2 Nuclear Energy Stocks to Buy Before 2026 Ends

Uranium spot prices rose from $43.08/lb at the end of January 2022 to $89.68/lb at the end of August 2026, with Bank of America projecting $130/lb in 2027 amid AI/data-center power demand and nuclear decarbonization investment. Uranium Energy is expected to grow revenue at a 59% CAGR from 2025-2028 to $270 million and reach positive adjusted EBITDA in 2027, though its $5.2 billion enterprise value equals 43x next-year sales. BWX Technologies ended 2025 with a $7.3 billion backlog, up 50% year over year and more than twice its $3.2 billion revenue, supported by U.S. naval nuclear and commercial nuclear demand.

Analysis

BWXT offers the cleaner risk-adjusted nuclear expression because its earnings are tied to qualification barriers, long-duration government procurement, and fabrication capacity rather than a single commodity curve. Its commercial optionality is not yet the core thesis: the nearer re-rating catalyst is sustained conversion of naval backlog into margin-bearing revenue and evidence that labor/material inflation is being recovered in contract pricing. Over 6-18 months, constrained domestic HALEU/TRISO and nuclear-component capacity could make BWXT a strategic bottleneck, supporting a premium multiple versus diversified defense peers.

UEC is effectively a levered spot-uranium vehicle already priced for a favorable commodity outcome. The critical variable is not broad AI-power demand rhetoric but whether utilities accelerate uncovered-volume contracting at prices high enough to justify restarting and expanding production; without that, a large portion of projected EBITDA remains duration-dated. In the next 1-3 months, UEC is vulnerable to uranium-price consolidation, equity issuance for growth, or a shift from spot buying to utility term contracts that dampens the visible spot market.

The consensus likely overstates the immediacy of data-center demand for uranium: new nuclear capacity takes years to permit, finance, and construct, while existing-reactor life extensions are more relevant near-term. Conversely, the market may underappreciate the defense-industrial constraint: naval fleet expansion, submarine maintenance, and domestic fuel-security policy can support BWXT even if commercial SMR deployment slips. The thesis is falsified for BWXT by backlog conversion/margin deterioration or delayed Navy awards; for UEC, by uranium holding below roughly $70/lb through 2027 or production growth failing to translate into unit-cost improvement.

Key Decisions for Investors

• Initiate/maintain a 6-12 month long BWXT position; target a 15-20% return from earnings multiple expansion and backlog conversion, with a 8-10% stop or reassessment if quarterly segment margins compress and funded backlog stalls.
• Express nuclear exposure as long BWXT / short UEC in equal dollar amounts over the next 3-6 months. The pair isolates execution-heavy defense/fabrication exposure against high-duration uranium-beta valuation risk; cover the short if uranium breaks materially above $100/lb on confirmed utility contracting rather than speculative spot flows.
• Do not add UEC outright until verifying quarterly realized uranium sales volumes, cash costs, committed contract coverage, and dilution needs. If spot uranium pulls back while those operating metrics improve, UEC becomes a higher-conviction 12-24 month call-option-style long; absent that evidence, risk/reward is unfavorable at a revenue-multiple-led valuation.
• Monitor U.S. appropriations, naval procurement awards, HALEU funding, and utility contracting disclosures as catalysts. A funded domestic fuel-policy package would favor BWXT and U.S.-based uranium suppliers; cancellation or delay of such support would most quickly compress the nuclear thematic premium.